Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.09 USD | +1.63% | -0.47% | -22.96% |
May. 10 | UBS Adjusts Rocket Pharmaceuticals Price Target to $51 From $54, Maintains Buy Rating | MT |
May. 10 | Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.96% | 2.1B | |
+5.66% | 111B | |
+11.23% | 105B | |
-2.24% | 21.93B | |
-12.15% | 22.34B | |
-5.75% | 18.59B | |
-36.52% | 18.12B | |
-10.09% | 16.96B | |
+3.33% | 13.7B | |
+36.58% | 12.45B |
- Stock Market
- Equities
- RCKT Stock
- News Rocket Pharmaceuticals, Inc.
- Transcript : Rocket Pharmaceuticals, Inc. Presents at Bank of America Securities 2023 Healthcare Conference, May-10-2023 04